Related Experiment Video
Updated: Jun 21, 2025
The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability
Published on: April 28, 2022
Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis
Burhanuddin Sohail Rangwala1, Varisha Zuhair1, Muhammad Saqlain Mustafa1
1Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan.
Insights
Iron supplementation with ferric carboxymaltose (FCM) in heart failure (HF) patients with iron deficiency (ID) reduces hospitalizations. However, FCM did not improve overall or cardiovascular mortality rates in this patient group.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Iron deficiency (ID) is prevalent in patients with heart failure (HF).
- ID in HF is linked to reduced quality of life, increased hospitalizations, and higher mortality.
- Effective management strategies for ID in HF are crucial.
Purpose of the Study:
- To evaluate the efficacy of iron supplementation with ferric carboxymaltose (FCM) in patients with chronic heart failure (HF) and iron deficiency (ID).
- To assess the impact of FCM on quality of life, hospitalization rates, and mortality in HF patients with ID.
Main Methods:
- A comprehensive literature search was conducted across electronic databases up to October 1, 2023.
- Meta-analysis included studies involving patients with HF and ID, comparing ferric carboxymaltose (FCM) treatment with placebo.
- Data from 5229 patients (2691 FCM, 2538 placebo) were analyzed.
Main Results:
- Ferric carboxymaltose (FCM) significantly reduced heart failure (HF)-related hospitalizations.
- No significant improvement was observed in overall mortality.
- Cardiovascular mortality rates were not improved by FCM treatment in patients with HF and ID.
Conclusions:
- Ferric carboxymaltose (FCM) is effective in reducing HF-related hospitalizations in patients with iron deficiency (ID).
- FCM does not appear to impact overall or cardiovascular mortality in this population.
- The findings support the use of FCM for managing iron deficiency in heart failure patients.
Abstract:
Aim: Iron deficiency (ID) is associated with heart failure (HF) in a considerable proportion of patients. To improve the quality of life, lower the frequency of hospitalizations, and lower mortality rates of chronic HF patients (HF), this meta-analysis will look into the role of iron supplementation using ferric carboxymaltose (FCM). Methods & results: From inception until 1 October 2023, we conducted a thorough literature search of electronic databases for peer-reviewed publications. Around 5229 HF patients were included, of which 2691 received FCM while 2538 received placebo. Conclusion: FCM reduces HF-related hospitalizations but doesn't improve overall or cardiovascular mortality in those with HF and ID. The overall results support FCM's role in managing iron deficiency in heart failure.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System